Contact
Please use this form to send email to PR contact of this press release:
Egle Therapeutics to Highlight Novel Preclinical Findings for Regulatory T Cells Targeting Programs EGL-001 and EGL-002 With Poster Presentations at the 2025 AACR Annual Meeting
TO: